"versionIdentifier","uuid:ID","instanceType","id","rationale"
"2","cb7c9d5e-9d0e-474b-84ab-4ca22370e976","StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
